2-Acetylcyclopentanone, an Enolate-Forming 1,3-Dicarbonyl Compound, Is Cytoprotective in Warm Ischemia-Reperfusion Injury of Rat Liver

Boleslav Kosharskyy, Amaresh Vydyanathan, Lihai Zhang, Naum Shaparin, Brian C. Geohagen, William Bivin, Qiang Liu, Terrence Gavin, and Richard M. LoPachin

Departments of Anesthesiology (B.K., A.V., L.Z., N.S., B.C.G., R.M.L.) and Pathology (W.B., Q.L.), Montefiore Medical Center, Albert Einstein College of Medicine, Bronx, New York; and Department of Chemistry, Iona College, New Rochelle, New York (T.G.)

Received November 24, 2014; accepted February 5, 2015

ABSTRACT

We have previously shown that 2-acetylcyclopentanone (2-ACP), an enolate-forming 1,3-dicarbonyl compound, provides protection in cell culture and animal models of oxidative stress. The pathophysiology of ischemia-reperfusion injury (IRI) involves oxidative stress, and, therefore, we determined the ability of 2-ACP to prevent this injury in a rat liver model. IRI was induced by clamping the portal vasculature for 45 minutes (ischemia phase), followed by recirculation for 180 minutes (reperfusion phase). This sequence was associated with substantial derangement of plasma liver enzyme activities, histopathological indices, and markers of oxidative stress. The 2-ACP (0.80–2.40 mmol/kg), administered by intraperitoneal injection 10 minutes prior to reperfusion, provided dose-dependent cytoprotection, as indicated by normalization of the IRI-altered liver histologic and biochemical parameters. The 2-ACP (2.40 mmol/kg) was also hepatoprotective when injected before clamping the circulation (ischemia phase). In contrast, an equimolar dose of N-acetylcysteine (2.40 mmol/kg) was not hepatoprotective when administered prior to reperfusion. Our studies to date suggest that during reperfusion the enolate nucleophile of 2-ACP limits the consequences of mitochondrial-based oxidative stress through scavenging unsaturated aldehyde electrophiles (e.g., acrolein) and chelation of metal ions that catalyze the free radical-generating Fenton reaction. The ability of 2-ACP to reduce IRI when injected prior to ischemia most likely reflects the short duration of this experimental phase (45 minutes) and favorable pharmacokinetics that maintain effective 2-ACP liver concentrations during subsequent reperfusion. These results provide evidence that 2-ACP or an analog might be useful in treating IRI and other conditions that have oxidative stress as a common molecular etiology.

Introduction

Significant hepatocyte damage occurs when blood flow to the liver is transiently interrupted (ischemia phase) and then subsequently restored (reperfusion phase). This sequence of warm ischemia-reperfusion injury (IRI) can occur either purposefully (e.g., during liver transplantation) or as part of disease pathogenesis (e.g., sinusoidal obstruction, Budd-Chiari syndrome). The pathophysiology of warm IRI involves oxidative stress, mitochondrial dysfunction, Kupffer cell activation, and increased proinflammatory cytokine signaling. These deleterious processes are initiated during the ischemic phase and subsequently exacerbated as a function of cellular reoxygenation during the reperfusion phase (Klune and Taung, 2010). Based on this pathogenic complexity, it has been difficult to identify primary mediators or mechanisms that might be relevant therapeutic targets. Nonetheless, oxidative stress appears to be a significant component of IRI (Papadopoulos et al., 2013), and the use of antioxidant compounds that decrease cellular levels of reactive oxygen species (ROS) is an obvious pharmacotherapeutic strategy. However, clinical trials provided only mixed support for antioxidant therapy (Jaeschke and Woolbright, 2012; Papadopoulos et al., 2013).

There is substantial evidence that the toxic consequences of oxidative stress are mediated by acrolein, 4-hydroxy-2-nonenal (HNE), and other unsaturated aldehydes generated during membrane lipid peroxidation (Uchida, 2003; Wood et al., 2006; Ellis, 2007; Yoshida et al., 2009). As reactive electrophiles, these aldehydes cause cytotoxicity by depleting cellular glutathione (GSH) levels and by reacting with functionally critical nucleophilic amino acid residues of proteins (Fritz and Petersen, 2013; LoPachin and Gavin, 2014). Therefore, as an alternative approach to antioxidants, nucleophilic chemicals that form irreversible adducts with these electrophiles...
might arrest oxidative damage and mitigate hepatocyte demise during reperfusion. Indeed, the thiol-based nucleophile, N-acetylcysteine (NAC), can reduce hepatocyte damage in animal models of IRI (Jegatheeswaran and Siriwardena, 2011). In previous studies, we showed that acetylacetone, 2-acetylcyclopentanone (2-ACP), and other 1,3-dicarbonyl compounds (Fig. 1A) provided direct protection in cell culture models of oxidative stress (H2O2) and electrophile (acrolein)-induced injury (LoPachin et al., 2011). These compounds ionize in aqueous solutions to form nucleophilic enolate anions (Fig. 1B). More recently, we demonstrated that 2-ACP prevented hepatotoxicity in a mouse model of acetaminophen overdose (Zhang et al., 2013). Whereas the idea that enolate-forming 1,3-dicarbonyl compounds, such as 2-ACP, might be cytoprotective is unprecedented, the concept stems from the recognition that curcumin (Fig. 1A), a phytophenol with well documented cytoprotective capability (Begum et al., 2008), also possesses an enolizable 1,3-dicarbonyl function (pKa = 8.0; LoPachin et al., 2011). Furthermore, the chemistry of 1,3-dicarbonyl compounds is well known (Loudon, 2002; Bug and Mayr, 2003), and mechanistic studies have shown that the nucleophilic enolate of 2-ACP (Fig. 1B) mediates cytoprotection by inhibiting oxidative stress at multiple sites (LoPachin et al., 2011, 2012; Zhang et al., 2013). Because oxidative stress is a major pathogenic component of IRI, in the present study we determined the relative hepatoprotective efficacies of 2-ACP and NAC in a rat model of warm liver IRI.

**Materials and Methods**

**Reagents.** All chemicals, reagents, and experimental protectants were of the highest grade commercially available and were purchased from Sigma-Aldrich (St. Louis, MO). Bovine heart mitochondrial preparations were purchased from BioVision (Milpitas, CA).

**Animals and Treatments.** All aspects of animal use in this study were in accordance with the National Institutes of Health Guide for Care and Use of Laboratory Animals and were approved by the Montefiore Medical Center Animal Care Committee. Adult male rats (Sprague-Dawley, 275–300 g; Taconic Farms, Germantown, NY) were used in this study. Rats were housed individually in polycarbonate cages. Filtered drinking water and Purina Rodent Laboratory Chow (Purina Mills, St. Louis, MO) were available ad libitum. The animal room was maintained at approximately 22°C and 50% humidity with a 12-hour light/dark cycle.

**IRI Model: Surgical Procedure.** Rats were fasted overnight with access to water, and experiments were begun the next morning. On the day of the experiment, rats were anesthetized (urethane, 1000 mg/kg i.p.), and the abdomen was shaved and swabbed with ethanol (70%), followed by a betadine preparation. A transverse abdominal incision (2.5 cm) was made, and the liver was elevated to expose the hepatic vasculature. Experimental IRI was induced according to a modification of Abe et al. (2009). Specifically, two atrumatic microclips (Roboz Surgical Instrument, Gaithersburg, MD) were used to cross-clamp the portal vein, hepatic artery, and bile duct above the right lateral lobe branch. This produced ischemia in the median and left lateral lobes (involving ~70% of the liver), which was visually evident due to blanching of the lobes. The abdominal incision was closed, and body temperature was maintained at 37°C by a thermostatically controlled heating pad. Following the ischemic period, the clamps were removed and circulation was restored. The abdomen was closed for the duration of the reperfusion phase. Immediately following this period, animals were euthanized by bilateral pneumothorax, and blood and tissue samples for the vehicle- and sham-operated controls were obtained for the surgical procedure, sham-operated animals received a laparotomy. At 45 minutes postlaparotomy, the incision was closed and animals were euthanized 180 minutes later. Analyses of the respective blood and tissue samples for the vehicle- and sham-operated controls indicated no group mean statistical difference, and therefore, these control groups were combined and designated as sham/vehicle control.

**Hepatotoxicity Parameters and Histopathological Analyses.** To assess IRI-induced hepatocyte damage, the appearance of liver enzymes, alanine aminotransferase (ALT), and aspartate aminotransferase (AST) in plasma was measured. In addition, plasma levels of lactate dehydrogenase (LDH) were determined as a general measure of cell damage. Cardiac blood was collected in heparin-coated tubes (1.5 ml; BD Biosciences, Franklin Lakes, NJ), and plasma samples were obtained by centrifugation (14,000g for 5 minutes). Samples were
subsequently analyzed by an automated analyzer (Hitachi Modular Automated Clinical Chemistry Analyzer; Roche Diagnostics, Indianapolis, IN) and expressed as IU/ml plasma.

As indices of hepatocyte oxidative stress, unsaturated aldehyde products of lipid peroxidation and soluble thiol status were determined in liver homogenates prepared from the different experimental groups. To measure tissue concentrations of the unsaturated aldehydes, HNE, and malondialdehyde (MDA), frozen livers were pulverized and samples (2 g) were added to 5.5 ml radioimmunoprecipitation assay buffer (DeSeau et al., 1987) containing protease inhibitor cocktail and butylated hydroxytoluene (5 mM). Tissue samples were homogenized in a Dounce tissue grinder (10 strokes), and the homogenate was centrifuged at 500g (4°C) for 15 minutes to remove cellular debris. The supernatant was retained (S1); the pellet was washed once in radioimmunoprecipitation assay buffer (4.5 ml); and the supernatant (S2) was combined with S1. Total (free and protein-bound) unsaturated aldehydes were determined by the spectrophotometric method of Gerard-Monnier et al. (1998), as modified by Zhang et al. (2013). Briefly, an aliquot (200 μl) of the combined supernatant was added to 650 μl 1-methyl-2phenylindole in an acetonitrile/methanol (3:1) mixture. The reaction was started by adding 150 μl 12 N hydrochloric acid. Absorbance (586 nm) was measured after incubation of the reaction mixture at 45°C for 60 minutes. The absorbance values used to determine MDA concentrations were based on a standard curve for 1,1,3,3-tetramethoxypropane as a source of MDA. To determine the respective HNE concentrations, parallel samples (200 μl) were added to the 1-methyl-2-phenylindole mixture, and the reaction was started by adding 150 μl methanol-sulfonic acid (37%) containing 100 μM Fe(III). Absorbance (586 nm) was measured after incubation at 45°C for 60 minutes. The final absorbance readings are linear functions of both the HNE and MDA concentrations, and, therefore, the HNE content can be derived by subtracting the previously determined MDA concentration from the combined unsaturated aldehyde content.

GSSG and oxidized glutathione (GSSG) levels were determined by the method of Giustarini et al. (2013). To analyze GSSG, rat livers were homogenized in Tris buffer (50 mM) containing serine (2 mM), boric acid (20 mM), aceticin (0.020 mM), and N-ethylmaleimide (31 mM) and then deproteinized by trichloroacetic acid (TCA) precipitation. Liver homogenates were centrifuged at 14,000g (2 minutes), and the supernatant (S1) was retained. Unreacted N-ethylmaleimide was extracted from S1 using 3 volumes of dichloromethane, followed by centrifugation at 14,000g (30 seconds). The resulting supernatant (S2) was collected and was added (20 μl) to a cuvette containing PBS (925 μl), 20 mM 5,5’-dithiobis(2-nitrobenzoic acid) (5 μl), 4.8 mM NADPH (20 μl), and 20 μM glutathione reductase (20 μl). As a blank, TCA (20 μl) was added to cuvettes in place of the S1 aliquot. Spectrophotometric absorbance was recorded at 412 nm (1 minute), and the sample slope or blank (TCA) slope was calculated. GSSG (0.10 μM) was subsequently added to the cuvette, and the absorbance was recorded at 412 nm for 1 minute. GSSG concentrations in liver homogenates (GSSG) were calculated using the following algorithm: GSSG = S × GSSGc/St × 49.5 (sample dilution factor) × 2 (dilution due to acidification/protein concentration (mg/ml), where S = slope sample – slope blank, GSSGc = is the final concentration of standard GSSG in the cuvette (0.10 μM), and St = (slope sample + GSSG) – slope sample. Results are expressed as nmol/mg liver protein (±S.E.M.). To measure total GSH, S1 (10 μl) or GSH (thiol source) standards (4–64 μM) were added to a cuvette containing PBS (945 μl), 20 mM 5,5’-dithiobis(2-nitrobenzoic acid) (5 μl), 4.8 mM NADPH (20 μl), and 20 μM glutathione reductase (20 μl). As a blank, TCA (20 μl) was added to cuvettes in place of the S1 aliquot. Spectrophotometric absorbance was recorded at 412 nm (1 minute), and total GSH was expressed as nmol/mg liver protein (±S.E.M.).

For histologic assessment, liver samples were excised from rats in all experimental groups at the conclusion of the respective reperfusion phases. Tissue samples were fixed in ice-cold 10% buffered formalin solution, paraffin embedded, sectioned (5 μm), and stained with H&E. Sections from individual animals (n = 3 per experimental group) were blinded by code, and 5–8 fields on each slide were randomly selected and evaluated at the light-microscopy level for evidence of hepatocellular injury using standard morphologic criteria (e.g., necrosis, loss of architecture, vacuolization, karyolysis, apoptosis). The extent of cellular injury was determined semiquantitatively by assigning a severity score on a scale of 0–4, as described by He et al. (2009), where 0 = absent; 1 = mild; 2 = moderate; 3 = severe; and 4 = complete hepatocyte destruction. This scoring system was used to compare the relative extent of liver damage associated with the IRI plus vehicle and IRI plus ACP experimental groups.

**Results**

**Characterization of the IRI Model.** The ischemia-reperfusion sequence used in these studies caused substantial hepatocyte injury, as evidenced by elevations in plasma ALT, a liver-specific enzyme. Figure 2 shows that mean (±S.E.M.) ALT plasma levels rose from a control value of 80 ± 10 U/I to 7360 ± 390 U/I after 180 minutes of postischemia reperfusion. Severe IRI-induced parenchymal cell damage was substantiated by commensurate increases in plasma levels of AST and LDH (Fig. 2; Bessem et al., 2006). These enzyme alterations coincided with histopathological analyses that indicated moderate to severe liver cell death (Fig. 3). Measurements of liver homogenates also indicated significantly elevated indices of cellular oxidative stress, that is, unsaturated aldehyde accumulation and GSH loss (Fig. 4). The IRI model used in this
study produces substantial liver damage and was therefore used to determine the relative hepatoprotective abilities of experimental protectants.

The 2-ACP Administered Prior to Reperfusion Is Hepatoprotective. Initial studies determined the ability of 2-ACP to prevent the expression of injury during the reperfusion phase. Results indicate that 2-ACP (0.80–2.40 mmol/kg) injected 10 minutes before unclamping the hepatic circulation produced significant dose-dependent reductions in ALT, AST, and LDH plasma levels reflecting hepatocyte protection (Fig. 2). The changes in plasma biomarkers corresponded to histopathological alterations noted in the different experimental groups. Thus, all tissue sections from the control group exhibited unremarkable liver histology, that is, no evidence of ischemia or hepatocyte injury (histologic score = 0; Fig. 3A). In contrast, tissue sections from the IRI plus vehicle group collected after 180 minutes of reperfusion exhibited severe, confluent hepatocyte necrosis involving all of zone 1 and focally extending into zone 2. Eosinophilic acellular/proteinaceous material comprised the areas of zonal necrosis. Also evident was severe lobular hepatocyte apoptosis and scattered foci of spotty necrosis (Fig. 3B). Correspondingly, histologic assessment revealed moderate-to-severe levels of hepatocyte injury, that is, a mean (±S.E.M.) score of 2.91 ± 0.21. However, when 2-ACP (2.40 mmol/kg) was injected 10 minutes before unclamping the hepatic circulation, this level of severe IRI-induced hepatocyte damage was significantly reduced. Histologic analyses of tissue slides from the IRI plus ACP group indicated mild ischemic changes with rare hepatocyte necrosis/apoptosis and no areas of confluent necrosis (Fig. 3C). Commensurate with these relatively mild cytologic changes, the respective histologic score (1.27 ± 0.17) was significantly lower than that of the IRI plus vehicle group.

As indices of cellular oxidative stress, unsaturated aldehydes (MDA and HNE), and GSH, GSSG concentrations were measured in liver homogenates prepared from the different experimental groups. Commensurate with histologic evidence of liver cell death (Fig. 3), the IRI plus vehicle group was associated with relatively large increases in mean concentrations of total MDA and HNE (Fig. 4A). However, these data primarily reflect changes in adduction of membrane-bound proteins because severe loss of cellular integrity during 180 minutes of reperfusion (Fig. 3) will permit egress of free aldehyde and the aldehyde adducts of soluble proteins. IRI was also associated with substantial reductions in GSH, which most likely represents loss due to electrophile scavenging (free radicals, unsaturated aldehydes), oxidation to GSSG, and cell lysis. The observed reduction in GSSG is consistent with several IRI-induced changes, that is, increased ATPase-mediated transport, elevated membrane permeability with subsequent efflux, formation of protein mixed disulfides, and the irretrievable loss of GSH substrate (Shivakumar et al., 1995). In accordance with histologic evidence of hepatocyte preservation and decreased lysis (Fig. 3), 2-ACP administered prior to reperfusion reduced the elevated aldehyde concentrations associated with IRI and limited corresponding GSH/GSSG perturbations (Fig. 4).

![Figure 2](image2.png)  
**Fig. 2.** Dose-dependent effects of 2-ACP administered intraperitoneally 10 minutes prior to unclamping the portal circulation (reperfusion phase) on IRI-induced plasma appearance of ALT, AST, and LDH in rat (n = 10–15/group). The 2-ACP at the 0.80 mmol/kg dose was not effective relative to IRI + vehicle (data not shown). Data are expressed as mean activity ± S.E.M., and joining lines indicate statistically significant differences in treatment groups at **P < 0.01 level.

![Figure 3](image3.png)  
**Fig. 3.** Representative photomicrographs illustrating parenchymal status in rat liver from control (A), IRI (B), and IRI + 2-ACP (C; 2.40 mmol/kg i.p.) experimental groups. Tissue was excised at the conclusion of the 180-minute reperfusion period, fixed, and then stained with H&E. The arrows on (B) (IRI group) denote the zonal distribution of severe, confluent hepatocyte necrosis involving the periportal regions. The perivenular regions remained viable. Magnification 100× (400× inset), and the scale bar equals 100 μm.
NAC Administered Prior to Reperfusion Is Not Hepatoprotective. NAC (2.40 mmol/kg i.p.) was administered prior to re-establishing hepatic circulation. In contrast to 2-ACP, an equimolar dose of NAC did not affect IRI-induced changes in the plasma levels of ALT, AST, or LDH (Fig. 5).

Hepatoprotective Effects of 2-ACP Administered Prior to Ischemia. As illustrated in Fig. 6, administration of 2-ACP by intraperitoneal injection 10 minutes before induction of liver ischemia significantly decreased (55–65%) the IRI-induced derangement of plasma enzymes. The same level of hepatoprotection can therefore be achieved when administered before either reperfusion (Fig. 2) or ischemia (Fig. 6).

The 2-ACP Does Not Inhibit Succinate Dehydrogenase Activity. Figure 7 shows that malonate, a well-described competitive inhibitor of mitochondrial SDH, produced concentration-dependent (50–500 μM) enzyme inhibition with an IC₅₀ of 147.4 ± 9.5 μM. These data are consistent with previous determinations of malonate inhibition of SDH in rat mitochondria (IC₅₀ = 42 μM; Wojtovich and Brookes, 2008) and in bovine heart submitochondrial particles (IC₅₀ = 96 ± 1.3 μM; Jones and Hirst, 2013). Figure 7 also shows that incubation of mitochondrial proteins with a broad concentration range of 2-ACP (500–1000 μM) did not significantly affect SDH activity.

HSAB Calculations of Unsaturated Aldehyde Electrophilicity and Hepatoprotectant Nucleophilicity. Table 1 presents the respective values of the HSAB parameters, softness (σ) and electrophilicity (ω), determined for acrolein and other unsaturated aldehydes that participate in oxidative stress injury. Results indicate that these aldehydes are soft, relatively strong electrophiles. For comparative purposes, we included the HSAB parameters for N-acetyl-p-benzoquinonimine, the very powerful quinone imine metabolite of acetaminophen (Tylenol; McNeil-PPC, Inc., Fort Washington, PA), and for acrylamide a very weak electrophile that produces cumulative neurotoxicity (see LoPachin and Gavin, 2014, for details). Table 2 presents the respective values of the HSAB parameters, softness (σ) and nucleophilicity (ω⁻), for GSH (endogenous thiol) and cytoprotective nucleophiles. The data show that 2-ACP, GSH, and NAC are soft, relatively nucleophilic compounds. Also presented are acidity constants expressed as pKₐ values and the corresponding percentage of each nucleophile in the anionic state (% ionization) at cytophysiological conditions. As indicated in Table 2, the thiolate anions are stronger nucleophiles, but 2-ACP is more acidic (lower pKₐ), and therefore, a greater proportion of this substance will exist in the ionized nucleophilic enolate state at physiologic pH.
Discussion

Previous research has indicated that 2-ACP and related 1,3-dicarbonyl compounds were effective cytoprotectants in cell culture and animal models of oxidative stress injury (LoPachin et al., 2011; Zhang et al., 2013). Oxidative stress also plays a prominent role in IRI, presumably through ischemic inhibition of mitochondrial SDH activity, which leads to disruption of electron transport during reperfusion and the generation of ROS (Papadopoulos et al., 2013; Chouchani et al., 2014). Accordingly, we found that 2-ACP injected prior to the reperfusion phase (Fig. 2) provided dose-dependent hepatoprotection against IRI. A similar level of protection was achieved when 2-ACP was administered prior to induction of ischemia (Fig. 6). Although pathogenic processes initiated during the ischemic episode might be targets for protection, it is more likely that 2-ACP selectively inhibits reperfusion-based mechanisms (see ahead). Because the ischemic period is short (45 minutes), and the presumed plasma half-life of 2-ACP is sufficiently long (\( \sim 12 \) hours; Ballantyne and Cawley, 2001), the observed hepatoprotective ability of 2-ACP injected prior to ischemia is probably due to maintenance of effective liver concentrations during reperfusion. Regardless of the injection sequence, the efficacy of 2-ACP hepatoprotection is clearly indicated by histologic preservation in the IRI plus ACP group (Fig. 3, C versus B) and by significant reductions in hepatocyte indices of oxidative stress (Fig. 4).

It is noteworthy that both 2-ACP and curcumin are enolate-forming 1,3-dicarbonyl compounds (Fig. 1). The chemical reactions of anionic enolates are well known (Loudon, 2002; Bug and Mayr, 2003; Eames, 2009), and the relevance of these reactions to general cytoprotection has been demonstrated (Vajragupta et al., 2005; Weber et al., 2006; Begum et al., 2008; LoPachin et al., 2011, 2012). Thus, 2-ACP is not a strong antioxidant (LoPachin et al., 2011), but will ionize readily in biologic buffers to yield a nucleophilic enolate (Fig. 1B). The enolate carbanion generated by this process can form 1,4-Michael addition products.

![Fig. 7](image)

**Fig. 7.** Concentration-dependent effects of malonate (50–500 \( \mu M \)) and 2-ACP (500–1000 \( \mu M \)) on the succinate dehydrogenase activity in bovine heart mitochondrial preparations. Data are expressed as mean percentage of control \( \pm \) S.E.M. The calculated IC\(_{50}\) for malonate = 147.4 \( \pm \) 9.5 \( \mu M \). The 2-ACP did not produce concentration-dependent changes in SDH activity, and therefore an IC\(_{50}\) could not be calculated.

<table>
<thead>
<tr>
<th>Electrophile</th>
<th>Structure</th>
<th>Softness ((s) \times 10^{-6}) ev (^2)</th>
<th>Electrophilicity ((\omega)) ev</th>
</tr>
</thead>
<tbody>
<tr>
<td>NAPQI</td>
<td><img src="image" alt="NAPQI" /></td>
<td>499</td>
<td>6.83</td>
</tr>
<tr>
<td>Acrolein</td>
<td><img src="image" alt="Acrolein" /></td>
<td>371</td>
<td>3.82</td>
</tr>
<tr>
<td>HNE</td>
<td><img src="image" alt="HNE" /></td>
<td>377</td>
<td>3.80</td>
</tr>
<tr>
<td>Crotonaldehyde</td>
<td><img src="image" alt="Crotonaldehyde" /></td>
<td>367</td>
<td>3.56</td>
</tr>
<tr>
<td>Malondialdehyde</td>
<td><img src="image" alt="Malondialdehyde" /></td>
<td>384</td>
<td>3.39</td>
</tr>
<tr>
<td>Acrylamide</td>
<td><img src="image" alt="Acrylamide" /></td>
<td>315</td>
<td>2.62</td>
</tr>
</tbody>
</table>

**TABLE 1**

HSAB parameters for unsaturated aldehydes

Softness \((s)\) and electrophilicity \((\omega)\) for the selected compounds were calculated as described in Materials and Methods. Nonaldehydes N-acetyl-p-benzoquinoimine (NAPQI) and acrylamide are included for comparative purposes.
adducts with acrolein, HNE, and other electrophilic unsaturated aldehydes that participate in oxidative stress–induced injury (LoPachin et al., 2011). Similarly, curcumin and other phytopolyphenols (e.g., phloretin, resveratrol) can ionize to form nucleophile enolate sites that scavenge electrophilic aldehydes (Awasthi et al., 1996; Zhu et al., 2009; 2012).

In cell culture models of acrolein toxicity, the rank order of cytoprotection for a series of enolate-forming 1,3-dicarbonyl compounds was found to be directly related to the respective reaction rates for acrolein adduct formation (LoPachin et al., 2011). These rates are determined by the following: 1) enolate nucleophilicity, which influences the second order rate constant (k) for the adduct reaction, and 2) the acidity of the parent dicarbonyl compound (pK_a), which governs the concentration of the reacting enolate nucleophile. Calculations of HSAB parameters indicate that acrolein and related unsaturated aldehydes are soft, relatively strong electrophiles (Table 1) that react preferentially with comparably soft nucleophiles. Experimental evidence indicates that the toxicologically relevant soft nucleophilic targets of the unsaturated aldehydes are sulfhydryl thiolate groups on specific cysteine residues that modulate the function of critically important enzymes and proteins (reviewed in LoPachin et al., 2012; LoPachin and Gavin, 2014). HSAB calculations (Table 2) show that the 2-ACP enolate is a soft, strong carbanion nucleophile, and, because the parent compound (2-ACP) is relatively acidic (pK_a = 7.8), a significant concentration of this anion will exist at physiologic pH. These data suggest that IRI hepatoprotection is mediated by the soft enolate of 2-ACP, which can act as a surrogate nucleophile target for acrolein and other soft electrophilic aldehydes generated during reperfusion (see detailed discussions in LoPachin et al., 2012; LoPachin and Gavin, 2014). The aldehyde-enolate interaction is a kinetically favored soft–soft reaction that is preferable to soft–hard interactions, for example, the reactions of acrolein with hard nucleophilic nitrogen groups on carnosine (histidine analog) or N-acetyl lysine (LoPachin et al., 2007, 2009b).

As indicated above, aldehyde scavenging by the enolate is dependent not only on softness and nucleophilicity, but also on the acidity of the parent compound. Thus, nucleophilicity (ω; Table 2) of the 2-ACP enolate is comparable to that of the respective thiolate forms of NAC and GSH. However, due to a lower pK_a value, the 2-ACP enolate will be present in significantly higher concentrations than either thiolate at physiologic conditions. This limited ionization at cellular conditions might explain the inability of NAC to prevent IRI in the present study (Fig. 5), because the relatively low concentration of the active species (thiolate) would consequently limit electrophile scavenging. In fact, there is evidence that NAC cytoprotection involves an indirect mechanism that is not based on electrophile scavenging, for example, increased GSH synthesis or mitochondrial bioenergetics (Zwingmann and Bilodeau, 2006; Jaeschke and Woolbright, 2012).

The bidentate enolate of 2-ACP can also arrest oxidative stress by chelating iron [Fe(III)] and copper [Cu(II)] metal ions (Jiao et al., 2006; Eames, 2009; LoPachin et al., 2011) that catalyze the free radical–generating Fenton reaction. Indeed, the metal-chelating abilities of 1,3-dicarbonyl enolates have been recognized for more than a century (Eames, 2009). Recent cell culture studies of H_2O_2 toxicity demonstrated that metal chelation was an important criterion for 1,3-dicarbonyl cytoprotection (LoPachin et al., 2011). In these studies, the relative chelating abilities for the dicarbonyl series were quantified by direct in chemico measurements (LoPachin et al., 2011). Thus, compounds with rigid structures that precluded bidentate metal ion coordination such as 1,3-cyclopentanedione were ineffective despite having the ability to form enolates. However, 2-ACP and other β-diketone compounds with flexible structures that accommodate metal chelation were highly protective. Metal ion chelation by the enolate of curcumin has also been identified as a cytoprotective trait of this phytopolyphenol (Bernabe-Pineda et al., 2004; Jiao et al., 2006).

Malonic acid is a 1,3-dicarbonyl compound that provides cytoprotection in several models of in vivo and in vitro IRI. However, cytoprotection is not based on enolate nucleophilicity, because this acid exists as the dianion (malonate) at physiologic conditions and further ionization would be extremely unfavorable if not precluded entirely. Instead, like other dicarboxylates, malonate is a succinate analog and is a competitive inhibitor of mitochondrial SDH. Substantial evidence now indicates that ischemia-induced reversal of this enzyme causes accumulation of succinate in mitochondria. During reoxygenation, SDH oxidation of the excess succinate drives ROS production through reverse electron transport involving complex I (reviewed in Chouchani et al., 2014). Malonate cytoprotection in IRI is presumably mediated by SDH inhibition, which prevents succinate accumulation and subsequent ROS production. The 2-ACP is also a 1,3-dicarbonyl compound, and therefore, the possibility exists that 2-ACP inhibition might mediate corresponding hepatoprotection. However, we have demonstrated that, even at relatively high concentrations, 2-ACP is not an effective inhibitor of mitochondrial SDH activity (Fig. 7). As a dicarboxylic acid derivative, malonate can inhibit SDH by acting as a structural analog of the citric acid cycle intermediate succinate. In contrast, 2-ACP is a β-diketone and is therefore not a suitable substrate inhibitor for SDH. These data indicate that the observed hepatoprotective ability of 2-ACP does not involve inhibition of enzyme activity.

Our results indicate that 2-ACP provided significant hepatoprotection in an animal model of IRI. The anionic enolate of this 1,3-dicarbonyl is a soft nucleophile that can form irreversible Michael adducts with acrolein, HNE, and other soft aldehyde electrophiles generated during the reperfusion phase of IRI. The

### Table 2: HSAB and ionization parameters for thiolate and enolate nucleophiles

<table>
<thead>
<tr>
<th>Compounds (Anion</th>
<th>Softness (ω x 10^3 ev^-1)</th>
<th>Nucleophilicity (ω' x 10^3 ev)</th>
<th>pK_a</th>
<th>% Anion (pH = 7.4)</th>
</tr>
</thead>
<tbody>
<tr>
<td>2-ACP (enolate)</td>
<td>418</td>
<td>204</td>
<td>7.8</td>
<td>28.5</td>
</tr>
<tr>
<td>GSH (thiolate)</td>
<td>427</td>
<td>239</td>
<td>8.6</td>
<td>5.9</td>
</tr>
<tr>
<td>NAC (thiolate)</td>
<td>367</td>
<td>316</td>
<td>9.5</td>
<td>0.8</td>
</tr>
</tbody>
</table>

Materials and Methods

Softness (ω) and nucleophilicity (ω'; acrolein as the reacting electrophile) for the selected compounds were calculated as described in Materials and Methods.
2-ACP can also reduce cellular oxidative stress through metal ion chelation and resulting inhibition of the free radical-generating Fenton reaction. Although these cytoprotective reactions of 2-ACP are consistent with the known chemistry of the 1,3-dicarbonyl compounds, it is possible that 2-ACP either directly or indirectly influences cellular stress responses (e.g., Nrf2/Keap1, Sirt1 pathways), as has been suggested for curcumin cytoprotection (Yang et al., 2009; Chung et al., 2010). The premise that enolate-forming 1,3-dicarbonyl compounds might be a possible therapeutic approach was based on the recognition that the heptadienone bridge of curcumin was also a 1,3-dicarbonyl (Fig. 1A). However, unlike most phytopolyphenols (Lambert et al., 2007; Halliwell, 2008), simple 1,3-diketones, such as 2-ACP, are chemically stable, relatively water-soluble compounds that are rapidly absorbed and have large volumes of distribution (Ballantyne and Cawley, 2001; LoPachin et al., 2011). Furthermore, the acute animal toxicity of these chemicals is low (LD50 > 500 mg/kg), and longitudinal dosing studies indicate a low incidence of systemic toxicity (e.g., 400–600 mg/kg per day × 60 days; Ballantyne and Cawley, 2001; B. Geohagan and R. LoPachin, unpublished data). The mechanism of cytoprotection, in conjunction with favorable pharmacokinetics and low toxicity, suggests that 2-ACP or an analog might be useful in treating warm IRI associated with stroke, myocardial infarction, and other organ failure. IRI-induced oxidative stress is also an underlying cause of allograft rejection that the heptadienone bridge of curcumin was also a 1,3-dicarbonyl (Fig. 1A). However, unlike most phytopo-

**Acknowledgments**


Address correspondence to: Dr. Richard M. LoPachin, Department of Anesthesiology, Montefiore Medical School, 111 E. 210th Street, Bronx, NY 10467. E-mail: lopachin@einstein.yu.edu